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Abstract Cushing’s syndrome (CS) has a considerable
negative impact on patient health-related quality of life
(HRQoL). Two disease-specific instruments (the Cushi-
ngQoL and the Tuebingen CD-25 questionnaire) are now
available to assess the impact of the disease and its treat-
ment on HRQoL. The purpose of this review was to
summarize the characteristics of the studies which have
used these two instruments to date and summarize their
findings regarding (a) the determinants of disease-specific
HRQoL in patients with CS and (b) the impact of treatment
for CS on disease-specific HRQoL. A total of 7 studies
were identified, 5 with the CushingQoL and 2 with the
Tuebingen CD-25. Most were observational studies,
though the CushingQoL had been used in one randomized
clinical trial. In terms of clinical factors, there was some
evidence for an association between UFC levels and dis-
ease-specific HRQoL, though the presence and strength of
the association varied between studies. There was also
some evidence that a more recent diagnosis of CS could
lead to poorer HRQoL, and that length of time with adrenal
insufficiency may also affect HRQoL. There was no evi-
dence for an impact on disease-specific HRQoL of etiology
or of the clinical signs and symptoms associated with CS,
such as bruising, rubor, and fat deposits. One factor which
did have a significant negative effect on HRQoL was the
presence of depression. No clear picture emerged as to the
effect of demographic variables such as age and gender on
HRQoL scores, though there was some evidence for poorer
HRQoL in female patients. As regards treatment, the two
interventions studied to date (transsphenoidal surgery and
pasireotide) both showed significant gains in HRQoL, with
moderate to large effect sizes. This type of review is useful
in summarizing knowledge to date and suggesting future
research directions.
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Introduction
Cushing’s syndrome (CS) is a rare endocrine disorder
caused by chronic exposure to hypercortisolism, with an
annual incidence of 2–3 cases per million [1]. It is most
often due to a pituitary adenoma (Cushing’s disease) but
may also be of adrenal origin (adenoma/s or carcinoma), or
due to an ectopic secretion of adrenocorticotrophin
(ACTH) by a tumor of any location.
The condition is more prevalent in females, who are at 3
times greater risk than males, especially in Cushing’s dis-
ease. Since CS leads to many physical problems, including
central obesity, gonadal dysfunction, hirsutism, muscle
weakness, hypertension, and hyperglycemia [2], as well as
to psychiatric and psychological disturbances in the active
hypercortisolemic state, such as major depression, mania,
anxiety disorders, and cognitive impairment, the condition
obviously has a profound effect on patients’ quality of life
[3]. The negative influence on quality of life extends into
areas such as body image, due to changes in physical
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appearance, as well as interference with family life and
relations with partners, and impaired school or work per-
formance [4]. Even after endocrine cure, patients score
lower on measures of general well-being, anxiety and
depression, and overall quality of life than healthy controls
[5]. The assessment of health-related quality of life
(HRQoL) is therefore of great relevance in patients with CS.
Health-related quality of life was initially assessed in CS
patients using generic measures such as the SF-36 [6] and
the SF-12 [7]. Measures of specific symptoms associated
with the disease, such as the Hospital Anxiety and
Depression Scale, were also used [8]. However, more
recently, two disease-specific measures, the CushingQoL
[9, 10] and the Tuebingen CD-25 [11, 12], have been
developed. In principle, disease-specific measures of
HRQoL should be able to tell us more about both the
dimensions which are particularly relevant to CS patients
as well as which factors influence HRQoL in CS patients.
Given that these questionnaires have now been used in
several studies, reviewing the results might help to provide
a clearer picture of how CS and its treatment affect
patients’ quality of life and potentially indicate directions
for future research with this type of instrument.
The objective of this paper was to describe the studies
performed to date using CS-specific HRQoL questionnaires
and to summarize their findings. We were particularly
interested in trying to establish what the determinants of
disease-specific HRQoL in CS patients are and on under-
standing how interventions for CS impact it.
Methods
This was a qualitative review of published studies for the
two questionnaires of interest and additional available data
for the CushingQoL. Published studies were identified
from a review of the literature and from the authors’ own
archives.
The CushingQoL questionnaire
CushingQoL is a disease-specific questionnaire designed to
assess HRQoL in CS. It is a self-administered instrument
consisting of 12 questions which cover the areas of trouble
sleeping, wound healing/bruising, irritability/mood swings/
anger, self-confidence, physical changes, ability to partici-
pate in activities, interactions with friends and family,
memory issues and future health concerns. Content for the
questionnaire was derived from interviews with 10 patients
with the condition [9]. Patients respond on Likert scales with
five response categories (‘Always’, ‘Often’, ‘Sometimes’,
‘Rarely’, and ‘Never’, or ‘Very much’, ‘Quite a bit’,
‘Somewhat’, ‘Very little’, and ‘Not at all’). Responses are
scored on a scale of 1–5, where ‘1’ corresponds to ‘Always’
or ‘Very much’ and ‘5’ to ‘Never’ or ‘Not at all’. The overall
score is calculated by summing responses on all items and
ranges from 12 (worst HRQoL) to 60 (best HRQoL). To
facilitate the interpretation of scores, they can be standard-
ized on a scale from 0 (worst HRQoL) to 100 (best HRQoL).
The Tuebingen CD-25 questionnaire
The Tuebingen CD-25 questionnaire was also developed as
a disease-specific questionnaire for patients with Cushing’s
disease. Items in the questionnaire were generated from a
review of the technical literature, interviews with patients,
and the rating of neurosurgeons, endocrinologists and a
neuropsychologist. The final version of the questionnaire
consists of 25 items measuring the subdomains of
Depression, Sexual Activity, Environment, Eating Behav-
iour, Bodily Restrictions, and Cognition. Response options
are on a five-point Likert scale from 0 (strongly disagree),
1 (somehow agree), 2 (sometimes agree), 3 (mostly agree),
and 4 (strongly agree). Each subscale and the total score
have a minimum score of 0 and a maximum score of 100,
with higher scores representing lower HRQoL.
Studies using the CushingQoL and Tuebingen
questionnaires
The two questionnaires have been used in a number of
studies or registries, as described below and summarized in
Table 1.
The CushingQoL validation study
This study [9] was performed in 5 European countries
(Spain, France, Germany, the Netherlands, and Italy)
between August and October 2006. CushingQoL was
administered to 125 patients aged 18 years or above with
histologically determined CS of pituitary or adrenal origin,
or whose hypercortisolism disappeared after adrenal or
pituitary surgery. Patients with CS due to adrenal carci-
noma, ectopic ACTH secretion, or exogenous treatment
with glucocorticoids were excluded. CushingQoL was self-
administered at a single study visit. Other data collected
included age, gender, level of education, current employ-
ment status, weight, height, blood pressure, date of diag-
nosis of CS and cause, history and persistence or not of
adrenal insufficiency and hypercortisolism, surgery under-
gone for the disease, and history, dose, and date of pituitary
radiotherapy, recent 24 h urinary free cortisol (UFC, within
the last 6 months), current pharmacological treatment,
concomitant diseases and their treatment, and hospital
admissions over the last year related to CS or its
complications.
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Randomized phase 3 study of pasireotide in Cushing’s
disease
This double-blind, phase 3 study tested the efficacy and
safety of pasireotide, a somatostatin analog with high
binding affinity for the somatostatin-receptor subtype 5. It
included 162 adults with CS and urinary free cortisol at
least 1.5 times the upper limit of the normal range who
received subcutaneous pasireotide at a dose of 600 lg (82
patients) or 900 lg (80 patients) twice daily. Patients with
urinary free cortisol not exceeding 2 times the upper limit
of the normal range and not exceeding the baseline level at
month 3 continued to receive their randomly assigned dose;
all others received an additional 300 lg twice daily. The
primary end point was urinary free cortisol at or below the
upper limit of the normal range at month 6 without an
increase in dose. Open-label treatment continued through
month 12. Health-related quality of life was measured with
the CushingQoL questionnaire. The main analysis focused
on the impact of pasireotide on clinical markers [13] while
further analyses examined the impact of the drug on
HRQoL [14]. The data were also used to further examine
the psychometric properties of CushingQoL.
The ERCUSYN registry
The European Registry on Cushing’s syndrome (ERCU-
SYN) [15] is a web-based, multicentre registry that enrolled
508 CS patients diagnosed between January 1st, 2000 and
October 31st, 2010 from 36 centers in 23 European coun-
tries. The registry used a mixture of prospective and retro-
spective recruitment, though primarily prospective (83 %
from 2008 onwards). Patients were classified, depending on
the diagnosis, into pituitary-dependent CS (PIT-CS), adre-
nal-dependent CS (ADR-CS), CS from an ectopic source
(ECT-CS), and CS from other etiologies (OTH-CS).
Patients with adrenal cancer were excluded. Data in the
ERCUSYN database included baseline demographic and
anthropometric characteristics, etiology of CS and diagno-
sis date, comorbidities, bone status, and CS therapy, among
others. Health-related quality of life was measured using the
CushingQoL and EQ-5D generic questionnaire. Long-term
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treatment outcomes were assessed using biochemistry and
imaging parameters, post-treatment hormone replacement
therapies, pituitary deficiencies, clinical features, HRQoL,
and bone status. Urine 24 h free cortisol (UFC) levels were
collected and assessed to determine whether they were
within the range of normal values.
Additional analysis was performed using data from the
ERCUSYN study for the current manuscript to analyze the
relationship between CushingQoL scores and clinical
variables and to assess the impact of transsphenoidal sur-
gery (TSS) on HRQoL.
Psychometric performance of the CushingQoL
questionnaire in conditions of real clinical practice
In this study [16], the authors aimed to evaluate the psy-
chometric properties of test–retest reliability and sensitivity
to change of the CushingQoL questionnaire under condi-
tions of usual clinical practice conditions in a tertiary
referral centre. To evaluate test–retest reliability, the
CushingQoL was administered twice to ‘cured’ patients,
and to patients with active hypercortisolism (‘‘active
group’’). Patients were considered cured if they had
Table 2 Main findings of studies reviewed
Study Main findings
Webb et al. [9] Significant differences on CushingQoL scores between patients with active [mean 46.1 (SD 22.6)] and controlled [mean
56.1 (SD 19.5)] disease (based on UFC levels) (P = 0.009)
Significant differences between patients with [mean 47.6 (SD 20.5)] and without [mean 56.1 (SD 22.3)] hypercortisolism
(P = 0.043)
Lower (poorer) CushingQoL scores in patients with a more recent diagnosis (last 2 years; mean score 44 ± 22) than in
those diagnosed earlier (mean score 59 ± 22; P \ 0.001)
Linear regression analysis showed that being female (P = 0.029) and having elevated UFC (P = 0.011) were the main
contributors to impaired HRQoL
Colao et al. [13] Differences in CushingQoL scores between patients with fully controlled mean UFC [58.0 (3.7)] and those with
uncontrolled UFC [51.5 (3.4)] were not statistically significant
No statistically significant differences were observed between groups classified by BMI, waist circumference, weight,
amount of facial rubor, striae, bruising, supraclavicular fat, dorsal fat, or Karnofsky scores
Consistent and significant differences related to depression. Mean CushingQoL scores in patients with minimal depression
[mean = 61.6 (SE = 2.2) at month 12] were significantly higher (better HRQoL) than for patients with severe levels of
depression based on the BDI-II [mean = 30.8 (SE = 6.9) at month 12]
A high percentage of patients showed a significant improvement in terms of HRQoL (with improvements over 10 points on
CushingQoL) at 3 months (50.0 % of patients), 6 months (48.0 %) and 12 months (52.0 %)
CushingQoL score improved by 11.1 points (95 % CI, 6.8–15.5) after 12 months of treatment with pasireotide,
representing effect sizes of 0.47 and 0.49 (for 600 ug)
Valassi et al. [15] No significant differences in CushingQoL score by etiology
In multiple regression analysis, only depression was found to independently predict lower CushingQoL scores
Transsphenoidal surgery produced improvements on CushingQoL from a mean (SD) score of 38.3 (22.1) at baseline to 56.6
after 12 months (a change of 18.3 points), representing an effect size of 0.82
Santos et al. [16] CushingQoL scores were worse in patients with active disease than in those defined as ‘cured’ (46 ± 15 vs. 58 ± 20,
P \ 0.05)
No differences were seen between males and females with active disease nor between patients with hypercortisolism of
adrenal and pituitary origin
No differences in score between patients who had undergone radiotherapy and those who had not
No statistically significant correlation was found between CushingQoL scores and age
Transsphenoidal surgery produced improvements on CushingQoL from a mean (SD) of 41 (15) at baseline to 54 (13) at
4 months (P \ 0.01) and 68 (17) at 9 ± 3 months post surgery (P \ 0.001), corresponding to effect sizes of
approximately 0.86 and 1.8, respectively. Sample size was small (n = 11)
Tiemensma et al.
[17]
Negative illness perceptions were associated with poorer HRQoL
Milian et al. [11,
12]
Non-linear correlation between Tuebingen CD-25 scores and patients’ age
Preoperative 24 h urinary free cortisol (UFC) levels correlated significantly with the subscale Cognition and only
marginally failed significance level for the subscale Eating Behaviour
Preoperative cortisol and ACTH levels did not correlate with any scale
Milian et al. [11,
12]
Female patients perceived worse HRQoL than men in the domains of depressive symptoms and social environment
(P \ 0.05)
190 Pituitary (2014) 17:187–195
123
demonstrated adrenal insufficiency or morning cortisol
suppression [\50 nmol/L] after 1 mg dexamethasone
overnight, and if repeated measurement showed normal
(\280 nmol/L) values for 24 h urinary free cortisol. To
evaluate sensitivity to change, the questionnaire was
administered to patients with active hypercortisolism at
baseline, on diagnosis of CS, and again at 4 ± 1.5 and
9 ± 3 months after successful surgery.
Impact of negative illness perceptions on HRQoL
after long-term remission of CS
In this study [17], 52 patients completed questionnaires
including the Illness Perception Questionnaire (IPQ)-
Revised, and CushingQoL to ‘‘explore illness perceptions,
as potentially modifiable psychological factors, in relation
to HRQoL in patients with long-term remission of CS’’.
Patients completed the questionnaires at home. Results
were compared with reference data from recent studies
including patients with vestibular schwannoma (n = 80),
acute (n = 35) or chronic (n = 63) pain, and chronic
obstructive pulmonary disease (COPD; n = 171).
The development of the Tuebingen Cushing’s disease
quality of life inventory (Tuebingen CD-25). Part I:
construction and psychometric properties
As the title indicates, this paper reports the procedures used
to develop and validate the Tuebingen CD-25. The vali-
dation part of the study was carried out in a sample of 63
patients with an established diagnosis of pituitary-depen-
dent CD, of whom 13 were recruited after admission for
operative treatment, 15 were newly diagnosed, as yet
untreated patients, and 35 had been operated on between
3 months and 9 years before participating in the validation
study [11]. Patients completed the items that would even-
tually constitute the Tuebingen CD-25 together with
additional potential items for the questionnaire which were
later discarded. They also completed the WHOQoL-BREF
[18] and the effect of hormone levels (preoperative ACTH,
serum cortisol levels, 24 h UFC) and age on Tuebingen
CD-25 scores were analyzed.
The development of the Tuebingen Cushing’s disease
quality of life inventory (Tuebingen CD-25). Part II:
normative data from 1,784 healthy people
The second phase in the development of the Tuebingen CD-
25 consisted of obtaining normative data from a healthy
control group (n = 1784) which could be compared with
the results obtained from the 63 CD patients. The healthy
control group was recruited via a German online internet
version of the questionnaire and additional information
about age, gender, and educational background was also
obtained. The healthy control group included 1,210 women
and 574 men with a mean age of 28.9 years [12].
Results
The main results of the review of the different studies using
disease-specific measures to assess HRQoL in patients with
CS are shown in Table 2.
Determinants of disease-specific HRQoL
In the original validation study [9], significant differences
were observed in CushingQoL scores between those with
active [mean 46.1 (SD 22.6)] and controlled [mean 56.1 (SD
19.5)] disease (based on UFC levels) (P = 0.009) and
between patients with [mean 47.6 (SD 20.5)] and without
[mean 56.1 (SD 22.3)] hypercortisolism (P = 0.043). The
authors also found poorer CushingQoL scores in patients
with a more recent diagnosis (last 2 years; mean score
44 ± 22) than in those diagnosed earlier (mean score
59 ± 22; P \ 0.001). In pituitary-dependent CD, they found
no differences between those with and without hypopitu-
itarism or between those who had prior pituitary radiother-
apy and those who had not. Linear regression analysis
showed that being female (P = 0.029) and having elevated
UFC (P = 0.011) were the main contributors to impaired
HRQoL, while time elapsed since diagnosis of adrenal
insufficiency was slightly but positively related with the
CushingQoL score (r = 0.35, P = 0.02); in other words, the
longer the duration of adrenal insufficiency, the greater the
impact on HRQoL. Current age and age at diagnosis were not
significantly correlated with CushingQoL scores and no
correlation was observed between time elapsed since surgery
and CushingQoL score nor between CushingQoL score and
the presence of adrenal insufficiency.
Analysis of data from the pasireotide clinical trial
showed a clear trend, after 12 months of treatment, to
differences in CushingQoL scores between patients with
fully controlled mean UFC [58.0 (3.7)] and those with
uncontrolled UFC [51.5 (3.4)], though the differences were
not statistically significant. Likewise, no statistically sig-
nificant differences were observed between groups classi-
fied by BMI, waist circumference, weight, amount of facial
rubor, striae, bruising, supraclavicular fat, dorsal fat, or
Karnofsky scores. In the same study, consistent and sig-
nificant differences were found at month 6 and month 12
related to depression. Specifically, CushingQoL mean
scores in patients with minimal depression [mean = 61.6
(SE = 2.2) at month 12] were significantly higher than for
patients with severe levels of depression based on the BDI-
II [mean = 30.8 (SE = 6.9) at month 12].
Pituitary (2014) 17:187–195 191
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In the ERCUSYN registry, no significant differences in
CushingQoL score were observed between patients with
pituitary dependent CD (mean score 40 ± 17), adrenal
dependent CS (mean score 39 ± 14), CS from an ectopic
source (mean score 27 ± 13), or those with other types of
CS (mean score 23 ± 2) studied at baseline. CushingQoL
data were only available in the ectopic and other group
from n = 6 and n = 2 patients, respectively. Multiple
regression analysis was carried out with ERCUSYN data in
which gender, age, diagnosis, delay to diagnosis, BMI,
depression, diabetes, and hypertension were independent
variables, and CushingQoL score the dependent variable.
Depression was the only variable found to independently
predict lower CushingQoL scores.
In the Santos et al. study [16], CushingQoL scores were
observed to be worse in patients with active disease than in
those defined as ‘cured’ (46 ± 15 vs. 58 ± 20, P \ 0.05).
No differences were seen between males and females with
active disease nor between patients with hypercortisolism of
adrenal and pituitary origin (although the authors reported a
trend for lower CushingQoL scores in patients of adrenal
origin), or between patients who had undergone radiotherapy
and those who had not. No statistically significant correlation
was found between CushingQoL scores and age.
In the study by Tiemensma et al. [17], the authors found
moderate to strong inverse correlations between results on
the different dimensions of the IPQ-R questionnaire and the
CushingQoL indicating that more negative illness percep-
tions were associated with poorer HRQoL. This was partic-
ularly true for the dimensions of ‘Illness identity’
(r = 0.659; P \ 0.01) and emotional representation
(r = 0.629; P \ 0.01).
In the Tuebingen development study [11], the authors
found a non-linear correlation between the Tuebingen CD-
25 scores and patients’ age; younger (21–30 years) and
middle-aged (51–60 years) patients had poorer HRQoL
than patients between 31 and 50 years and those over
61 years of age. They also found that preoperative 24 h
urinary free cortisol (UFC) levels correlated significantly
with the subscale Cognition and only marginally failed
significance level for the subscale Eating Behaviour, while
preoperative cortisol and ACTH levels did not correlate
with any scale. In the Tuebingen normative study, the
authors observed that female patients perceived a worse
HRQoL than men in the domains depressive symptoms and
social environment (P \ 0.05).
Impact of interventions for CS, and changes in HRQoL
over time
Three of the studies reviewed [13, 15, 16] included repe-
ated measurements with CushingQoL and examined the
impact of different interventions on patients’ disease-
specific HRQoL. To date, no longitudinal studies have
been performed with the Tuebingen CD-25 questionnaire.
In the pasireotide study, CushingQoL score improved by
11.1 points (95 % CI, 6.8–15.5) after 12 months of treat-
ment with the study drug [13]. Effect sizes for changes at
6–12 months were 0.57 and 0.57 for 900 ug and 0.47 and
0.49 for 600 ug, respectively, which would represent
moderate effect sizes [14, 19]. Degree of control of UFC
was also found to be important, with clinically meaningful
improvements (i.e. an improvement of more than 10.1
points of the CushingQoL score) observed in patients
whose UFC levels were controlled or partially controlled at
month 6. A high percentage of patients showed a signifi-
cant improvement in terms of HRQoL (with improvements
over 10 points on CushingQoL) at 3 months (50.0 % of
patients), 6 months (48.0 %) and 12 months (52.0 %). On
the other hand, there were no clinically meaningful
improvements in the group with uncontrolled UFC.
Data from the ERCUSYN registry showed that trans-
sphenoidal surgery (TSS) produced improvements on
CushingQoL from a mean (SD) score of 38.3 (22.1) at
baseline to 56.6 after 12 months (a change of 18.3 points),
corresponding to an effect size of 0.82 (large effect size).
The Santos et al. [16] study showed similar results for TSS,
with CushingQoL scores improving from a mean (SD) of
41 (15) at baseline to 54 (13) at 4 months (P \ 0.01) and
68 (17) at 9 ± 3 months post surgery (P \ 0.001). In this
case too, the differences correspond to effect sizes of
approximately 0.86 and 1.8, respectively, although the
sample size used for this analysis was small (n = 11).
In terms of correlations in change scores, in the pa-
sireotide study the authors found a moderate correlation of
-0.40 (P \ 0.01) between changes in the CushingQoL
score and changes in mean UFC from baseline to month 12,
with increasing CushingQoL scores (improved HRQoL) as
mean UFC levels declined. Statistically significant corre-
lations (P \ 0.01) were also observed between changes in
CushingQoL score and changes in BMI (r = -0.31),
weight (r = -0.32), and BDI-II (r = -0.59). Only small
or null correlations were observed between changes in
CushingQoL scores and sitting systolic blood pressure,
waist circumference, facial rubor, striae, brusing, supra-
clavicular fat pad, and dorsal fat pad (though there were
some differences between the 600 and 900 ug drug dose
groups). Furthermore, based on a minimally important
difference (MID, the smallest clinically relevant difference
in CushingQoL score) of 10.1 [20], there was a clinically
meaningful improvement in CushingQoL scores at month 6
in patients whose UFC levels were controlled (n = 27;
mean improvement 12.8; SD = 15.1) or partially con-
trolled at month 6 (n = 17; mean improvement: 10.7;
SD = 20.8), but the improvement in CushingQoL scores
did not quite reach the MID in the uncontrolled group
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(n = 29; mean improvement: 9.9; SD = 21.8). Interest-
ingly, in additional analyses carried out with data from the
pasireotide study [14] it was found that of patients who
completed 12 months of therapy in that trial, 80 % had
either a reduction in diastolic blood pressure C5 mmHg
(58 %), a decrease in weight C7 % (42 %), or an
improvement CMID on CushingQoL (46 %) (mean ± SD,
11.1 ± 15.2). Improvements in symptoms and HRQoL
were maintained at 12 months.
Discussion
This review of studies which have evaluated HRQoL in CS
using disease-specific questionnaires has indicated a num-
ber of findings which may help to understand the rela-
tionship between the clinical features of Cushing’s
syndrome, its treatment, and HRQoL.
In terms of clinical factors, there is some evidence for an
association between UFC levels and disease-specific
HRQoL, though the strength of the association varied
between studies. There was also some evidence that a more
recent diagnosis of CS could lead to poorer HRQoL, and
that length of time with adrenal insufficiency (though not
the presence of the condition) may also affect HRQoL. On
the other hand, there is no evidence to date for an impact of
etiology or of the clinical signs and symptoms associated
with CS, such as bruising, rubor, and fat deposits, on dis-
ease-specific HRQoL. This latter finding may be somewhat
surprising, though the apparent lack of effect may have
been due to the low numbers of patients with moderate to
severe levels of those symptoms, in the one study which
examined this aspect. One factor which did have a signif-
icant negative effect on HRQoL was the presence of
depression. This was clearly seen in two of the studies
reviewed.
No clear picture emerged as to the effect of demo-
graphic variables such as age and gender on HRQoL
scores, though there was some evidence in two of the
studies that female patients scored lower than males on
CushingQoL and on some of the Tuebingen CD-25
dimensions. Poorer HRQoL in females is also consistent
with the findings of other studies both in patients [21, 22]
and the general population [23]. Finally, as regards treat-
ment, the two interventions studied to date (TSS and pa-
sireotide) both showed significant gains in HRQoL, with
moderate to large effect sizes.
Obviously, the findings of the present review should be
taken as provisional given the small number of studies and
the characteristics of some of the studies, such as the low
number of patients in some sub-groups. It should also be
borne in mind that the association between some clinical
variables, such as UFC levels and HRQoL can be obscured
by the fact that even those patients who have achieved a
long-term cure can still report decreased HRQoL, with
physical and psychosocial impairments, especially in the
presence of hypopituitarism [5]. Furthermore, variations
are known to exist in UFC measurements both methodo-
logically and physiologically on a day-to-day basis [13].
Regarding the effect of treatment, it is interesting to note
that changes observed with pasireotide from baseline to
6–12 months were comparable to the differences observed
between patients with active and non-active disease (dif-
ferences of approximately 10–11 points on CushingQoL).
Similarly, although treatment with pasireotide showed
slightly lower changes than those obtained with TSS,
CushingQoL score at 6 months in patients treated with the
drug (53.5) was similar to that seen in patients 6 months
after receiving TSS (54.4). Based on their CushingQol
scores, patients in the surgical group started from a lower
baseline HRQoL than those treated with pasireotide.
In relation to the measurement of change over time with
these instruments, it is of note that earlier studies suggested
a ‘ceiling’ for HRQoL in CS patients, at least using a
generic HRQoL instrument [24]. It would be interesting to
determine whether a similar effect exists with disease-
specific instruments, as may be suggested by the fact that
both pasireotide and TSS appeared to achieve similar
CushingQoL scores after 6 months. In that sense, the ini-
tiative by the developers of the Tuebingen CD-25 to obtain
normative scores from patients and healthy controls is
positive [12]. It would be useful to have such normative
scores for CushingQoL as well, if possible, as they provide
clinicians and researchers with a reference point or
benchmark for evaluating their own populations, and can
help determine what might be realistic upper levels of
HRQoL. Other avenues for future research include a closer
investigation of the relationship between CS signs and
symptoms such as bruising, rubor, and striae, and HRQoL.
The lack of evidence for an effect in the present review
may have been due to the low numbers of patients with
moderate to severe levels of the symptoms, but that should
be confirmed in future studies with larger numbers of
patients. Future studies could also attempt to clarify whe-
ther female patients do, in fact, have poorer HRQoL when
measured using disease-specific instruments and, if so, to
try to identify the dimensions affected, as that can indicate
areas to which interventions could be targeted.
Finally, we noted that the presence of depression quite
consistently showed a negative effect on CushingQoL
scores. This is perhaps not surprising, given previous evi-
dence showing the impact of depressive symptoms on
HRQoL in a range of pathologies and conditions [25–27].
Clearly, this is a factor to be taken into account both when
planning studies and analyzing their results, and when
deciding on management of CS patients. Studies using
Pituitary (2014) 17:187–195 193
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HRQoL as an endpoint should consider including a mea-
sure of depression such as the BDI-II to be able to control
for this potentially confounding factor in analyses. Future
studies could also examine whether interventions to treat
the depression have a positive impact on disease-specific
HRQoL in CS patients.
In conclusion, we have reviewed studies and other
applications of HRQoL questionnaires in CS patients to try
to clarify what are the determinants of HRQoL in these
patients and how treatment impacts results on HRQoL
questionnaires specific to the disease. There appears to be
some evidence that elevated, uncontrolled levels of UFC
are associated with poorer HRQoL, and that improving
UFC control leads to better HRQoL, and also that
depression is an important factor for poorer HRQoL in
these patients. On the other hand, there is currently no or
only weak evidence for an impact of other signs and
symptoms, and etiology on disease-specific HRQoL. Fur-
ther studies are required into these areas, and the impor-
tance of having normative, reference scores for disease-
specific questionnaires has been noted. This type of review
is useful in summarizing knowledge gained with these
questionnaires to date and suggesting future avenues of
research.
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